CLINICS
New evidences on the regulation of SF-1 expression by POD1/TCF21 in adrenocortical tumor cells
Monica Malheiros França,’ Antonio M. Lerario,” Maria Candida B.V. Fragoso,” Claudimara Ferini Pacicco Lotfil,*
‘Departamento de Anatomia, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP, BR. “Laboratorio de Hormonio e Genetica Molecular (LIM-42), Unidade Adrenal, Divisao de Endocrinologia, Faculdade de Medicine, Universidade de Sao Paulo, Sao Paulo, SP, BR.
OBJECTIVES: Transcription Factor 21 represses steroidogenic factor 1, a nuclear receptor required for gonadal development, sex determination and the regulation of adrenogonadal steroidogenesis. The aim of this study was to investigate whether silencing or overexpression of the gene Transcription Factor 21 could modulate the gene and protein expression of steroidogenic factor 1 in adrenocortical tumors.
METHODS: We analyzed the gene expression of steroidogenic factor 1 using qPCR after silencing endogenous Transcription Factor 21 in pediatric adrenal adenoma-T7 cells through small interfering RNA. In addition, using overexpression of Transcription Factor 21 in human adrenocortical carcinoma cells, we analyzed the protein expression of steroidogenic factor 1 using Western blotting.
RESULTS: Transcription Factor 21 knockdown increased the mRNA expression of steroidogenic factor 1 by 5.97-fold in pediatric adrenal adenoma-T7 cells. Additionally, Transcription Factor 21 overexpression inhibited the protein expression of steroidogenic factor 1 by 0.41-fold and 0.64-fold in two different adult adrenocortical carcinoma cell cultures, H295R and T36, respectively.
CONCLUSIONS: Transcription Factor 21 is downregulated in adrenocortical carcinoma cells. Taken together, these findings support the hypothesis that Transcription Factor 21 is a regulator of steroidogenic factor 1 and is a tumor suppressor gene in pediatric and adult adrenocortical tumors.
KEYWORDS: TCF21; POD1; SF-1; siRNA-POD1; Adrenocortical Tumor Cells.
França MM, Lerario AM, Fragoso MC, Lotfi CF. New evidences on the regulation of SF-1 expression by POD1/TCF21 in adrenocortical tumor cells. Clinics. 2017;72(6):391-394
Received for publication on September 17, 2016; First review completed on December 12, 2016; Accepted for publication on February 14, 2017 *Corresponding author. E-mail: clotfi@usp.br
INTRODUCTION
Transcription Factor 21 (Tcf21, POD1, capsulin, epicardin) is a basic helix-loop-helix (bHLH) transcriptional regulatory protein that is expressed in mesenchymal cells (1) at sites of mesenchymal-epithelial interaction in the developing urogenital (2), cardiovascular, respiratory, and gastrointest- inal systems (3). In the adrenal gland, POD1 is expressed exclusively in the capsule region of the adrenal cortex, as shown in mice expressing a lacZ gene reporter under the control of the regulatory region of Pod1 (4). In the testicles of fetal mice, POD1 represses steroidogenic factor 1 (SF-1/Nr5a1), an orphan member of the nuclear receptor family of transcrip- tion factors required for gonadal development, sex determina- tion and the regulation of adrenal and gonadal steroidogenesis in adult mice (5). Alterations of SF-1 dosage regulate compen- satory adrenal growth after unilateral adrenalectomy,
proliferation and tumorigenesis in mice (6). In humans, SF-1 is associated with adrenocortical tumorigenesis both in children (7) and adults (8). POD1 represses Sf-1/SF-1/SF-1 expression in mouse (5), rat (9), and human adrenocortical cells (10). Moreover, POD1 is downregulated in adrenocor- tical carcinoma (ACC) (10,11), melanoma (12), lung, and head and neck squamous cell carcinomas (13). In human ACC cells, we showed that POD1 binds to the SF-1 E-box promoter sequence and inhibits SF-1 expression and ster- oidogenic acute regulatory (StAR) expression, which is controlled by SF-1 (10). However, it is unknown whether silencing the POD1 gene promotes increased expression of the SF-1 gene. Accordingly, here, we analyzed the expression of the SF-1 gene after downregulation of endogenous POD1 expression in pediatric adrenocortical tumor cells. Moreover, we verified whether POD1 overexpression causes inhibition of SF-1 protein expression.
MATERIALS AND METHODS
Cell cultures and cell culture transfection
The NCI-H295R adult human ACC cell line (14) and ACC- T36 (10), a 6th-10th passage secondary adult human ACC cell line, were cultured and transfected as described by França et al. (10). Cells from the ACA-T7 pediatric secondary cell
Copyright @ 2017 CLINICS - This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/ 4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
DOI: 10.6061/clinics/2017(06)10
A.
B.
H295R
pCMVMyc
pCMVMycPod1
ACC-T36
pCMVMyc pCMVMycPod1
ß-actin
43kDa
ß-actin
SF1
54kDa
SF1
SF1 protein relative expression
1.5.
SF1 protein relative expression
2.5
p = 0.004
2.0
p=0.05
1.0-
4
1.5-
0.5-
1.0-
0.5
0.0
H295R
pCMVMyc
pCMVMycPod1
0.0
ACC-T36
pCMVMyc pCMVMycPod1
C.
D.
POD1 mRNA relative expression
SF1 mRNA relative expression
15
1.5
p=0.001
p=0.05
4
1.0-
10-
0.5-
5-
0.0
0
ACA-T7 cells
siNeg
siPOD1
ACA-T7 cells
siNeg
siPOD1
line were obtained from a functioning adrenocortical adenoma (ACA) as described by Almeida et al. (15). Pediatric adenoma (weight: 10 g; stage I) was diagnosed in a 1.1-yr-old girl with mixed Cushing’s syndrome and virilization (15). The adreno- cortical tumor cells were maintained at 37℃ in a fully humid- ified 95% air-5% CO2 environment and cultured in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The experiments were performed at the 10th-15th passage of the pediatric ACA culture cells. Briefly, 1.5 x 105 ACA-T7 cells were plated into six-well tissue culture plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA). After 24 h, the cells were transfected with small interfering RNA (siRNA-POD1) or posi- tive or negative high CG RNAi Stealth (Invitrogen, Carlsbad,
CA, USA) to a final concentration of 100 nM, combined with 9 ul of RNAiMax Lipofectamine® according to the manufac- turer’s instructions (Invitrogen, Carlsbad, CA, USA).
Total RNA extraction and qPCR siRNA (qRT-PCR)
Total RNA was extracted using TRIzol® reagent (Invitrogen) 48 h after transfection. The synthesis of cDNA and RT-qPCR analysis were performed as described by França et al. (10). A cycle threshold (Ct) value in the log-linear phase of ampli- fication was selected for each sample in triplicate and was normalized to the ß-actin expression level. Reactions were conducted in triplicate. Data were analyzed using the 2-44Ct method (16).
Immunoblotting
For the protein assay, H295R and ACC-T36 cells were plated and transfected as described by França et al. (17). The cells were lysed 72 h post-transfection in RIPA buffer containing protease and phosphatase inhibitors (Sigma Aldrich Gmbh, Steinheim, Germany). The total protein concentration was determined using the Bradford assay. Total protein lysates (30 µg) were resolved by 12% SDS-PAGE and gels were blotted onto nitrocellulose membranes after electrophoresis. Non-specific binding sites were blocked for 2 h with 0.1% bovine serum albumin (BSA) or 5% non-fat dried milk in TBST (TRIS-buffered saline solution containing 1% Tween 20). All washes and antibody incubations were performed using TBST. The following primary antibodies were used: anti-SF-1 (RD Systems Inc., Minneapolis, MN, USA; 1:1000) in blocking buffer (5% non-fat dried milk in TBST) and anti-actin (1:1000) in TRIS-buffered saline containing 1% Tween 20. Proteins were visualized using enhanced chemiluminescence (ECL) detec- tion with secondary HRP-conjugated anti-rabbit (Amersham Hybond ECL, Freiburg, Germany) or anti-mouse (Jackson ImmunoResearch Inc., West Grove, PA, USA) antibodies. Immunoblot results were quantified on a densitometer using GeneSnap and GeneTools software (SynGene-Synoptic Ltd., Cambridge, United Kingdom). Protein transfer and loading were monitored using Ponceau S staining of the membranes. The experiments were repeated in full at least three times, and SF-1 protein expression was normalized to the levels of B-actin.
Statistical analysis
Data are presented as the mean ± standard deviation (SD) of three independent replicate experiments. Data were analyzed using the Kruskal-Wallis test (non-parametric one-way ANOVA) or paired t-tests, when indicated. The results were considered significant when p<0.05.
RESULTS AND DISCUSSION
SF-1 protein levels in the H295R cell line (Figure 1A) decreased 0.41 + 0.11-fold (p=0.004) compared to those in the empty plasmid controls, whereas in ACC-T36 cells (Figure 1B), SF-1 protein expression decreased 0.64 ± 0.22-fold (p=0.05). These results are in agreement with a previous study show- ing that POD1 inhibited SF-1 mRNA expression in ACC cells (10). Next, we investigated whether knockdown of POD1 could increase SF-1 expression. To knockdown POD1, we used siRNA in ACA-T7 cells that expressed POD1 constitu- tively (data not shown) and determined the mRNA levels of POD1 and SF-1 in ACA-T7-siRNA-transfected and ACA- T7-siPOD1-transfected cells. POD1 mRNA expression was significantly lower in T7-siPOD1 transfected cells (0.35 ± 0.22-fold), with a 65% decrease compared to that in trans- fected controls (ANOVA, p=0.001; Figure 1C), whereas the mRNA levels of SF1 increased 5.97 ± 0.22-fold in T7-siPOD-1 cells compared to those in transfected controls (ANOVA, p=0.05; Figure 1D). These results support a role for POD1/ TCF21 as a regulator of SF-1 expression in adrenocortical tumor cells. Considering that POD1 is a repressor of SF-1 expression, that increased SF-1 dosage can trigger human adrenocortical cell proliferation (18), and that SF1 amplifica- tion (19) and SF1 overexpression (7) are characteristic of child- hood adrenocortical tumors, the results of our study improve the knowledge of how the tumorigenic process is controlled in adrenocortical tumor cells. Taken together, the findings of this
study and the POD1 inactivation observed in several types of tumors suggest that POD1 may act as a tumor suppressor in pediatric and adult adrenocortical tumors.
ACKNOWLEDGMENTS
M.M.F. received a scholarship (2010/00771-9) from the São Paulo Research Foundation (FAPESP) and C.F.P.L. received funding from FAPESP (2012/ 21839-6), the National Council for Scientific and Technological Develop- ment (CNPq), and the Office of the Dean for Research at the University of São Paulo.
AUTHOR CONTRIBUTIONS
Lotfi CF conceived the project. Lotfi CF and França MM designed the experiments. Lotfi CF, França MM, Lerario AM and Fragoso MC analyzed the data. França MM performed the experiments. França MM and Lotfi CF wrote the manuscript.
REFERENCES
1. Lu J, Richardson JA, Olson EN. Capsulin: a novel bHLH transcription factor expressed in epicardial progenitors and mesenchyme of visceral organs. Mech Dev. 1998;73(1):23-32, http://dx.doi.org/10.1016/S0925- 4773(98)00030-6.
2. Quaggin SE, Vanden Heuvel GB, Igarashi P. Pod-1, a mesoderm-spcific basic-helix-loop-helix protein expressed in mesenchymal and glomerular epithelial cells in the developing kidney. Mech Dev. 1998;71(1-2):37-48, http://dx.doi.org/10.1016/S0925-4773(97)00201-3.
3. Robb L, Mifsud L, Hartley L, Biben C, Copeland NG, Gilbert DJ, et al. epicardin: A novel basic helix-loop-helix transcription factor gene expressed in epicardium, branchial arch myoblasts, and mesenchyme of developing lung, gut, kidney, and gonads. Dev Dyn. 1998;213(1):105-13, http://dx.doi.org/10.1002/(SICI)1097-0177(199809)213:1 <105 :: AID-AJ A10>3.0.CO;2-1.
4. Kim AC, Barlaskar FM, Heaton JH, Else T, Kelly VR, Krill KT, et al. In search of adrenocortical stem and progenitor cells. Endocr Rev. 2009; 30(3):241-63, http://dx.doi.org/10.1210/er.2008-0039.
5. Tamura M, Kanno Y, Chuma S, Saito T, Nakatsuji N. Pod-1/Capsulin shows a sex- and stage-dependent expression pattern in the mouse gonad development and represses expression of Ad4BP/SF-1. Mech Dev. 2001; 102(1-2):135-44, http://dx.doi.org/10.1016/S0925-4773(01)00298-2.
6. Beuschlein F, Mutch C, Bavers DL, Ulrich-Lai YM, Engeland WC, Keegan C, et al. Steroidogenic factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy. Endocrinology. 2002;143(8): 3122-35, http://dx.doi.org/10.1210/endo.143.8.8944.
7. Pianovski MA, Cavalli LR, Figueiredo BC, Santos SC, Doghman M, Ribeiro RC, et al. SF-1 overexpression in childhood adrenocortical tumours. Eur J Cancer. 2006;42(8):1040-3, http://dx.doi.org/10.1016/j.ejca.2006. 01.022.
8. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, et al. High diagnostic and prognostic value of steroidogenic factor-1 expres- sion in adrenal tumors. J Clin Endocrinol Metab. 2010;95(10):E161-71, http://dx.doi.org/10.1210/jc.2010-0653.
9. França MM, Abreu NP, Vrechi TAM, Lotfi CF. POD-1/Tcf21 over- expression reduces endogenous SF-1 and StAR expression in rat adrenal cells. Braz J Med Biol Res. 2015;48(12):1087-94, http://dx.doi.org/10.1590/ 1414-431X20154748.
10. França MM, Ferraz-de-Souza B, Santos MG, Lerario AM, Fragoso MC, Latronico AC, et al. POD-1 binding to the E-box sequence inhibits SF-1 and StAR expression in human adrenocortical tumor cells. Mol Cell Endocrinol. 2013;371(1-2):140-7, http://dx.doi.org/10.1016/j.mce.2012. 12.029.
11. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 2009;15(2):668-76.
12. Arab K, Smith LT, Gast A, Weichenhan D, Huang JP, Claus R, et al. Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogenesis. 2011;32(10):1467-73, http://dx.doi. org/10.1093/carcin/bgr138.
13. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA. 2006;103(4): 982-7, http://dx.doi.org/10.1073/pnas.0510171102.
14. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, et al. Establishment and Characterization of a Human Adrenocortical Carcinoma Cell Line That Expresses Multiple Pathways of Steroid Bio- synthesis. Cancer Res. 1990;50(17):5488-96.
POD1/TCF21 Knockdown increases SF-1 expression França MM et al.
15. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, et al. Expression of insulin-like growth factor-II and its receptor in pedi- atric and adult adrenocortical tumors. J Clin Endocrinol Metab. 2008; 93(9):3524-31, http://dx.doi.org/10.1210/jc.2008-0065.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8, http://dx.doi.org/10.1006/meth.2001.1262.
17. França MM, Ferraz-de-Souza B, Lerario AM, Fragoso MCBV, Lotfi CFP. POD-1/TCF21 Reduces SHP Expression, Affecting LRH-1 Regulation and Cell Cycle Balance in Adrenocortical and Hepatocarcinoma Tumor Cells.
Biomed Res Int. 2015;2015:841784, http://dx.doi.org/10.1155/2015/ 841784
18. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, et al. Increased steroidogenic factor-1 dosage triggers adreno- cortical cell proliferation and cancer. Mol Endocrinol. 2007;21(12):2968-87, http://dx.doi.org/10.1210/me.2007-0120.
19. Figueiredo BC, Cavalli LR, Pianovski MA, Lalli E, Sandrini R, Ribeiro RC, et al. Amplification of the steroidogenic factor 1 gene in child- hood adrenocortical tumors. J Clin Endocrinol Metab. 2005;90(2):615-9, http://dx.doi.org/10.1210/jc.2004-0942.